Modafinil is a wakefulness promoting agent for oral administration. The precise mechanism of action is unknown, however, it is theorized that it may exert its stimulant effects by decreasing GABA-mediated neurotransmission.

**Pre-Authorization Criteria:**

Modafinil may be approved for the following:

1. Narcolepsy
2. Excessive sleepiness due to Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
3. Excessive sleepiness due to Shift Work Sleep Disorder (SWSD)

The diagnosis must be established by a Psychiatrist, Endocrinologist, Internist or Sleep Specialist, however, once the diagnosis has been established the PCP may monitor the treatment and prescribe refills, as necessary.

*Off label uses of Modafinil for Attention-deficit/hyperactivity disorder (ADHD), cancer related severe fatigue, major depressive disorder, and multiple sclerosis-related fatigue are not covered unless documentation meets VCHCP’s policy on Coverage of Prescription Medication for Off-Label Use.*

*Note: Modafinil is not approved for pediatric patients under the age of 16 for any indication. Note: Brand Name Provigil is not a covered medication.*

Dosing: For Narcolepsy and OSA-initial 200mg once daily in AM. Doses up to 400mg once daily have been well tolerated, but there is no consistent evidence that this dose confers additional benefit. For SWSD-200mg as a single dose about 1 hour prior to start of work shift.

Dosage Forms: Oral tablet 100mg, 200mg
Revision History:
Date Developed: 1/22/18 by Catherine Sanders, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>